Provided are a UV light-responsive hyperbranched poly-(β-amino ester having high-efficiency gene delivery ability and a preparation method and application thereof; said poly-β-amino ester uses 4-amino-1-butanol, 2-nitro-1, M-phthaloyl 3-diacrylate, trimethylolpropane triacrylate, and 1-(3-aminopropyl)-4-methylpiperazine as raw materials, is polymerized by means of the “A2+B3+C2” Michael addition method, causing it to have a hyperbranched structure. In comparison with a linear structure, the branched structure enhances the interaction between the polymer and the nucleic acid molecule, significantly improving gene condensation ability, while also increasing cellular uptake by means of enhancing the interaction with the cell membrane. The poly-(β-amino ester has a UV-responsive group on the backbone chain; under UV light irradiation, the poly-(β-amino ester can be rapidly degraded after endocytosis, and releases the encapsulated genes, and achieves efficient gene transfection and reduces material toxicity. The invention has good prospects for development in the field of biomedical materials, and particularly in gene delivery.

The present disclosure provides nanoparticles comprising methyl palmitate and at least one serumglobular protein and uses thereof.

The present disclosure provides pharmaceutical compositions comprising a compound having activity as an ACVR1 (ALK2) or ALK5 inhibitor.

The present disclosure provides pharmaceutical compositions comprising a compound having activity as an ACVR1 (ALK2) or ALK5 inhibitor.

The present application provides methods and compositions for treating cancer by administering a composition comprising nanoparticles that comprise an mTOR inhibitor (such as a limus drug) and a carrier protein (such as an albumin) based upon the mutation status of TSC1 or TSC2 and one of VHL, RBI, PBRIM1, K.DM6A, RET, SETD2 ARID 1 A, BAP1, BRCA2, TP53, RBI, ATRX, FLT1, NTRK1, TLX3, KDM6A, CDH4, CDKN2C, DAXX, ERBB3, GNAS, IL7R, PDGFRB, PMS2, PTEN, SMARCA4, and YY1AP1.

The present application provides methods and compositions for treating cancer by administering a composition comprising nanoparticles that comprise an mTOR inhibitor (such as a limus drug) and a carrier protein (such as an albumin) based upon the mutation status of TSC1 or TSC2 and one of VHL, RBI, PBRIM1, K.DM6A, RET, SETD2 ARID 1 A, BAP1, BRCA2, TP53, RBI, ATRX, FLT1, NTRK1, TLX3, KDM6A, CDH4, CDKN2C, DAXX, ERBB3, GNAS, IL7R, PDGFRB, PMS2, PTEN, SMARCA4, and YY1AP1.

The present inventors have developed printable collagen bioinks using unmodified type I collagen with mechanical and structural properties that facilitate application to tissue in a structured form. In particular, the compositions of the present invention may be used to apply collagen gels to tissue (e.g. eye) using two- or three-dimensional (extrusion) bioprinting techniques.

The present inventors have developed printable collagen bioinks using unmodified type I collagen with mechanical and structural properties that facilitate application to tissue in a structured form. In particular, the compositions of the present invention may be used to apply collagen gels to tissue (e.g. eye) using two- or three-dimensional (extrusion) bioprinting techniques.

Provided herein are compositions comprising a nanoparticle and a D20 tag. The D20 tag comprises dibenzocyclooctyne (DBCO) covalently attached to a protein. Also provided are diagnostic and therapeutic methods utilizing the nanoparticle composition.

Provided herein are compositions comprising a nanoparticle and a D20 tag. The D20 tag comprises dibenzocyclooctyne (DBCO) covalently attached to a protein. Also provided are diagnostic and therapeutic methods utilizing the nanoparticle composition.